William Rice
Chief Executive Officer at APTOSE BIOSCIENCES INC.
Net worth: 56 799 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Daniel Douglas von Hoff | M | 76 |
Cylene Pharmaceuticals, Inc.
 Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | 27 years |
| Bernd Seizinger | M | 67 | 9 years | |
| Warren Whitehead | M | 71 | 13 years | |
| Susan Pietropaolo | F | - | - | |
| Deborah Brown | F | - | 7 years | |
| Carol Ashe | F | 66 | 6 years | |
| Denis Burger | M | 80 | 17 years | |
| Mark Vincent | M | 71 | 17 years | |
| Erich Maximilian Platzer | M | 74 | 10 years | |
| Shaun A. Kirkpatrick | M | - |
Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | 19 years |
| C. Payne | M | 61 | 2 years | |
| Reinhard Ambros | M | 67 |
Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | - |
| Peter J. Feinstein | M | - |
Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | - |
| S. Torres | M | 61 |
Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | - |
| Jon Patton | M | - | 4 years | |
| Raymond J. Dingledine | M | - |
Emory University School of Medicine
| 32 years |
| Rafael Bejar | M | 53 | 4 years | |
| Victor Montalvo-Lugo | M | - | 5 years | |
| Thomas Heineman | M | - | 4 years | |
| Fred Middleton | M | 74 |
Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | - |
| Brooks Ensign | M | - | - | |
| Marc Wiles | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bradley Thompson | M | 67 | 19 years | |
| Mary Fenton | F | 60 | 18 years | |
| Aiping H. Young | M | 67 | 15 years | |
| Milind Deshpande | M | 68 | 17 years | |
| James M. Garvey | M | 77 | 1 years | |
| Jotin Marango | M | 45 | 3 years | |
| William Brinkley Dickerson | M | - |
Emory University
| 8 years |
| Jim A. Wright | M | - | 15 years | |
| Edwin Levy | M | - | 9 years | |
| Damian Georgino | M | 63 |
Emory University
| 3 years |
| William H. Brewster | M | - |
Emory University
| 4 years |
| Michael Moore | M | - | - | |
| J. Lievonen | M | - | 15 years | |
| Richard S. Egosi | M | 61 |
Emory University
| 5 years |
| Jerome Birnbaum | M | 84 | - | |
| Ben Marzouk | M | - |
Emory University
| 7 years |
| John T. Parker | M | 59 |
Emory University
| 6 years |
| Janet Clennett | F | - | - | |
| Michael B. Weiss | M | - |
Emory University
| 4 years |
| Gary S. Weinstein | M | - |
Emory University
| 7 years |
| James Dinning | M | 71 | 12 years | |
| Claire S. Padgett | M | - |
Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | - |
| Jason S. Fisherman | M | 67 | 20 years | |
| David Louis Geller | M | - |
Emory University
| 4 years |
| Ger J. van Amersfoort | M | - | 9 years | |
| Robert B. Schultz | M | - | 16 years | |
| Neal Sessions | M | 60 |
Emory University
| 6 years |
| Gregory K. Chow | M | 51 | 8 years | |
| William E. Bechtold | M | - |
Emory University
| 10 years |
| David Thomas | M | - |
Emory University
| 4 years |
| Bill H. Chenoweth | M | - |
Emory University
| 7 years |
| Barry Snyder | M | 61 |
Emory University
| 4 years |
| Victor A. Allums | M | 65 |
Emory University
| 4 years |
| Leonard Kruimer | M | 66 | 3 years | |
| Herb Abramson | M | 83 | 6 years | |
| Alan Tuchman | M | 77 | 5 years | |
| Caroline Loewy | F | 58 | 4 years | |
| Jill C. Finder | F | - |
Emory University
| 4 years |
| David Adelman | M | 60 |
Emory University
| 3 years |
| Baxter Hayes | M | - |
Emory University
| 2 years |
| Deborah Ann Wean | F | - |
Emory University
| 3 years |
| Jay Fraser | M | - |
Emory University
| 4 years |
| Catherine Zacks Gildenhorn | F | - |
Emory University
| 3 years |
| Jack Smith | M | 72 |
Emory University
| 2 years |
| Rob S. Weisbein | M | - |
Emory University
| 4 years |
| Phil B. Phillips | M | - |
Emory University
| 4 years |
| Michael Kevin McCarty | M | - |
Emory University
| 5 years |
| Mark L. Wulkan | M | - |
Emory University
| 3 years |
| Lee Lazarus | M | 58 |
Emory University
| 4 years |
| Raj Dani | M | 54 |
Emory University
| 5 years |
| Julian Emanuel | M | - |
Emory University
| 4 years |
| Michael Aaron Cole | M | - |
Emory University
| 5 years |
| Jeff M. Swygert | M | - |
Emory University
| 4 years |
| Jeffrey C. Hummel | M | 59 |
Emory University
| 3 years |
| R. Haynes Chidsey | M | - |
Emory University
| 4 years |
| Matthew Cohen | M | 58 |
Emory University
| 4 years |
| John E. Webster | M | - |
Emory University
| 2 years |
| Adam Mayblum | M | 57 |
Emory University
| 4 years |
| Rick Rieder | M | - |
Emory University
| 4 years |
| Gregory W. Nelson | M | 61 |
Emory University
| 3 years |
| Eric Ende | M | 55 |
Emory University
| 4 years |
| Jeffrey Howard Schwartz | M | 65 |
Emory University
| 4 years |
| Michael J. Mufson | M | - |
Emory University
| 2 years |
| Susan Potto | F | - |
Emory University
| 4 years |
| Gustavus A. Puryear | M | 55 |
Emory University
| 4 years |
| Alyson G. Beasley | F | 56 |
Emory University
| 4 years |
| Linda Davis Taylor | F | - |
Emory University
| 1 years |
| Nelson Marc Braff | M | - |
Emory University
| 3 years |
| Brad Stern | M | 56 |
Emory University
| 4 years |
| Babak Yaghmaie | M | - |
Emory University
| 4 years |
| Andrew M. Fishman | M | - |
Emory University
| 4 years |
| Mitchell Lewis | M | 62 |
Emory University
| 4 years |
| Jon Solodar | M | - |
Emory University
| 4 years |
| Nancy J. Hull | F | - |
Emory University
| 4 years |
| Steve Shapiro | M | 59 |
Emory University
| 4 years |
| Andres Gutiérrez | M | 63 | 2 years | |
| Robert E. Tritt | M | - |
Emory University
| 3 years |
| Rebecca Gaskin Gain | F | 58 |
Emory University
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 68 | 68.00% |
| Canada | 33 | 33.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- William Rice
- Personal Network
